<DOC>
	<DOCNO>NCT00732966</DOCNO>
	<brief_summary>Most Angiotensin receptor blocker 's ( ARBs ) metabolize cytochrome P4502C9 ( CYP2C9 ) , one major isoforms cytochrome P450 human liver microsome . The purpose study evaluate whether CYP2C9 polymorphism significant clinical influence blood pressure lower effect losartan valsartan . Weather genetic importance choose right ARB right patient .</brief_summary>
	<brief_title>Ocsaar CYP2C9 Ploymorphism , Is There Connection Between Pharmacokinetics , Pharmacodynamics Pharmacogenetics ?</brief_title>
	<detailed_description>Losartan , first angiotentsin II receptor blocker ( ARB ) , know reduce blood pressure ( BP ) . The LIFE study , Cardiovascular Morbidity Mortality Losartan Intervention Endpoint Reduction , show losartan prevent cardiovascular morbidity mortality ÃŸ receptor blocker atenolol . This effect independent BP lower effect . Left ventricular hypertrophy ( LVH ) know cardinal manifestation BP independent risk factor cardiovascular complication . In patient subgroup isolate systolic hypertension , losartan find reduce cardiovascular cause mortality reverse LVH . ARBs use treatment hypertension , alone combination antihypertensive drug , calcium channel blocker , diuretic angiotensin I convert enzyme ( ACE ) inhibitor . ACE inhibitor ARBs may also important role prevention type II diabetes consider first line agent hypertensive patient impaired fast glucose metabolic syndrome . Most ARBs metabolize cytochrome P4502C9 ( CYP2C9 ) , one major isoforms cytochrome P450 human liver microsome . It convert losartan pharmacologically active metabolite EXP-3174 ( E-3174 ) . Other ARBs telmisartan olmesartan innate CYP2C9 , whereas candesartan valsartan metabolize pharmacologically inactive metabolite . Maximal concentration drug reach two hour post administration . Fourteen percent orally administer medication convert E-3174 , 10 40 fold potent losartan . The pharmacokinetics losartan E-3174 linear , dose dependent change repetitive administration . The CYP2C9 gene three main polymorphic variation cause single nucleotide polymorphism ; common allele CYP2C9*1 ( Arg144 Ile359 ) , two less common CYP2C9*2 ( Cys 144Ile359 ) CYP2CP*3 ( Arg144Leu359 ) code enzyme decrease activity . The oxidation losartan decrease 2,3 40 fold individual genotyped CYP2C9*1*3 , CYP2C9*2*3 CYP2C9*3*3 compare individual genotyped CYP2C9*1*1.CYP2C9*3 find influence losartan 's metabolism CYP2C9*2 . The distribution CYP2C9 allelic variant within different ethnic group varies . In Caucasians allele frequency CYP2C9*1 , CYP2C9*2 CYP2C9*3 report 0.79-0.86 , 0.08-0.135 0.03-0.085 respectively , whereas low frequency allele CYP2C9*2 CYP2C9*3 report Asian population ( 0 0.02-0.05 respectively ) . Ashkenazi Jews find similar prevalence allele polymorphism North American Caucasian population ( CYP2C9*1 , *2 , *3 allele frequency 0.772 , 0.140 0.086 , respectively ) . Nakai K et al . evaluate population prevalence different allele four different ethnic group Israeli population : Ashkenazi , Moroccan , Libyan Yemenite Jews . They find Ashkenazi population , prevalence CYP2C9*1 , CYP2C9*2 CYP2C9*3 variant 0.83 , 0.17 0.15 respectively , Yemenite population 0.89 , 0.1 0.15 respectively , Moroccan population 0.81 , 0.19 0.23 respectively Libyan population 0.69 , 0.27 0.31 respectively . Many drug find substrate CYP2C9 , include fluoxetine , losartan , phenytoin , tolbutamide , torsemide , warfarin , numerous NSAIDs . CYP2C9 activity inducible rifampicin possibly also carbamazepine , ethanol phenobarbitone . Several drug report inhibit CYP2C9 activity vivo vitro , example : fluconazole , amiodarone , trimethoprim , fluvastatin , cimetidine chloramphenicol . An vitro study demonstrate clearance losartan reduce significantly human liver microsome obtain CYP2C9*3*3 CYP2C9*2*2 homozygous individual , CYP2C9*3*1 heterozygous individual CYP2C9*2*1 individual . In study , clear conclusion could make regard CYP2C9*2*3 genotype . In another study , influence CYP2C9 polymorphism pharmacokinetics losartan E-3174 find single oral dose 50 mg losartan . Irbesartan undergoes metabolism CYP2C9 inactive metabolite . Hallberg P et al . randomly assign 115 hypertensive patient treat atenolol irbesartan . They find CYP2C9 genotype predict BP response irbesartan influence effect atenolol . Purpose : The purpose study evaluate whether CYP2C9 polymorphism significant clinical influence BP lower effect losartan valsartan . Weather genetic importance choose right ARB right patient . Methods Patients : A screening period conduct hypertensive patient age 18 year , undergo genetic evaluation CYP2C9 polymorphism . Patients sign write informed consent inclusion study . No change patient ' medication regimen make . Study design : The study prospective non randomize trial . All patient fulfil inclusion exclusion criterion treat losartan 50 mg daily one month . After wash period one week losartan treatment replace valsartan 160 mg daily . Patients evaluated baseline follow losartan valsartan treatment . Patients undergo 24 hour ambulatory BP monitoring baseline , one month follow losartan treatment one month follow valsartan treatment . Creatinine Potassium level measeured baseline one week follow drug administration , blood sample collect measure losartan/ E-3174 ration . Genetic evaluation : Polymerase chain reaction amplification preform use specific primer . Genotyping polymorphic CYP2C9 gene make use real time PCR ( RT PCR ) technology Roche light cycler . The procedure make closed system decrease chance contamination . Losartan E-3174 Analysis : The losartan e-3174 assay perform use reversed phase high performance liquid chromatography ( HPLC ) method . Hewlett Packard HP-1090 Series II use .</detailed_description>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>The study include 30 patient 3 prevalent allele CYP2C9 *1 , *2 and*3 , 10 patient group . Patients treat losartan valsartan prior enrollment study , Patients BP 140 systolic 90 diastolic ambulatory 24 hour BP monitoring , acute coronary syndrome 6 month previous study , Renal failure creatinin level 1.5 mg/dL , hyperkalemia ( K &gt; 5 mg/dL ) , Hematologic solid malignancy pregnancy . Patients also exclude study know use one drug induce inhibit CYP2C9 , rifampicin carbamazepine , ethanol , phenobarbitone , fluconazole , amiodarone , trimethoprim , fluvastatin , cimetidine chloramphenicol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>cyp2c9</keyword>
	<keyword>losartan</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>